New Weight-Loss pill VCT220 enters final testing phase
Disease control
Ongoing
This phase 3 trial tests whether VCT220, a daily pill that targets GLP-1 receptors, can help overweight or obese adults lose weight. About 840 participants will take either a high dose, low dose, or placebo for 12 months. The main goals are to see how much weight they lose and ho…
Phase: PHASE3 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC